What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?  

The results of DUO-E are very exciting and will serve a number of purposes. I was encouraged to continue to see that the combo of chemo IO performed better than chemo alone confirming the class effect that was seen in GY018 and RUBY. I wish there was a pre-planned comparison of the chemo/IO/Olaparib...

Based on the results of the primary objectives of DUO-E, I would only consider chemo+durva+olaparib in the pMMR patient however, I do not truly know the benefit of adding olaparib to IO in this patient population. I would like to see trials designed to compare chemo+IO versus chemo+IO+olaparib in th...